News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Dec 22, 2011
Porton Down, UK; 22nd December 2011: GW Pharmaceuticals plc (AIM:GWP) today announced that the Medical Products Agency in Sweden has granted regulatory approval for Sativex® (Delta-9-Tetrahydro-cann
Dec 11, 2011
Porton Down, UK; 12 December 2011: GW Pharmaceuticals plc is delighted to announce that Professor Roger Pertwee, GW’s Director of Pharmacology and an internationally recognised cannabinoid scientist
Nov 22, 2011
Porton Down, UK, 22 November 2011: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, announces its preliminary results for the year ended 30
Nov 22, 2011
Porton Down, UK; 22 November 2011: GW Pharmaceuticals plc (AIM: GWP) today announces that it has submitted an application under the European Mutual Recognition Procedure (MRP) to seek to expand the
Nov 17, 2011
Porton Down, UK; 17 November 2011: GW Pharmaceuticals plc (AIM: GWP) today announces that the European Patent Office has granted a patent which protects the composition of the Sativex® formulation.
Oct 24, 2011
Porton Down, UK; 24 October 2011: GW Pharmaceuticals plc (AIM:GWP) is pleased to note the announcement by Almirall, S.A.
Jul 18, 2011
Porton Down, UK; 18 July 2011: GW Pharmaceuticals plc (AIM:GWP) today announces the launch in Denmark of Sativex® oromucosal spray as a treatment for the relief of spasticity in Multiple Sclerosis (
Jul 04, 2011
Porton Down, UK; 4 July 2011: GW Pharmaceuticals plc (AIM:GWP) today announces the launch in Germany of Sativex® (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) oromucosal spray as a tre
Jun 30, 2011
Porton Down, UK; 30 June 2011: GW Pharmaceuticals plc (AIM: GWP) today announced the initiation of a second Phase III Sativex® clinical trial in the treatment of pain in patients with advanced cance
Jun 08, 2011
- The Danish Interior and Health Minister approves Sativex®, the first cannabis-based medicine in Denmark -

Pages